NCT02675829: Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

NCT02675829
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior therapy with Kadcyla/ado-trastuzumab emtansine (patients who had prior Herceptin/trastuzumab or other HER2 targeted agents are eligible)
https://ClinicalTrials.gov/show/NCT02675829

Comments are closed.

Up ↑